Michele Spina

Dr. Michele Spina


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Rosa Di LiddoRosa Di Liddo
Rosa Di Liddo
FNFilippo Naso
Filippo Naso
AGAlessandro Gandaglia
Alessandro Gandaglia
GSGiulio Sturaro
Giulio Sturaro
MSMichele Spina
Michele Spina
RMRobert J Melder
Robert J Melder
Introduction. Over the past two decades, the αGal (Galα1–3Galβ1–4GlcNAc–R) epitope, a carbohydrate found in many non-primate mammals, has gained significant relevance in medicine due to its association with an increasing number of allergic reactions to animal-derived foods, drugs, and medical devices. Due to the mutated gene coding for α1,3-galactosyltransferase (α1–3GT), humans lack αGal and, therefore, naturally produce anti-α-Gal antibodies (IgM, IgA, and IgG), especially in the context of a xenotransplantation, which can lead to extreme immunological reactivity, including hyperacute rejection of the transplant. Recently, these uncontrollable immune reactions have driven demand for more accurate procedures to better detect αGal in animal-derived foods or bioprosthetics. The currently most widely used α-Gal-specific monoclonal antibody is an IgM antibody (clone M86), developed in Ggta1 KO mice and isolated from hybridoma tissue culture. As the IgM isotype has limited purification properties, specificity, and sensitivity, we aimed to produce a novel IgG antibody with high affinity and extensive applicability. Methods. An experimental murine IgG1 anti-αGal antibody (IgG-αGalomab) was developed by immunization of Ggta1 knockout (KO) mice, and its affinity was evaluated using ELISA, Western blot, flow cytometry, and immunohistochemistry/immunofluorescence. Results. Compared to IgM-M86, IgG-αGalomab demonstrated ~1200-fold higher binding potency and lower cross-reactivity with competitive molecules, i.e., bovine serum albumin, galactobiose, and lactose. Unlike IgM-M86, IgG-αGalomab showed an increasing affinity over time in the binding tests performed on xenogeneic tissues. Notably, high-affinity for αGal was detected by Western blot at high dilution [1:200,000] of IgG-αGalomab compared to IgM-M86 [1:1,000]. By flow cytometry, specificity and dose-dependent response were confirmed using in vitro cultures of porcine and human fibroblasts. Finally, αGal demonstrated to be detectable by IgG-αGalomab at the dilution of [1:1,000] while IgM-M86 at that of [1:100] in immunofluorescence and immunohistochemistry analysis. Conclusions. Altogether, our newly developed antibody showed high sensitivity and specificity for α-Gal in various applications. Based on its potential binding capacity, IgG-αGalomab could have important applications in precision medicine for predicting, treating, and preventing immune-mediated phenomena of patients in different medical areas.

22 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FNFilippo Naso
Filippo Naso
ACAndrea Colli
Andrea Colli
PZPeter Zilla
Peter Zilla
ACAntonio Maria Calafiore
Antonio Maria Calafiore
CLChaim Lotan
Chaim Lotan
MSMichele Spina
Michele Spina
Rationale The presence of preformed antibodies against αGal in the human lead to opsonization of the implanted bioprosthetic heart valve (BHV), leading to deterioration and calcification. Murine subcutaneous implantation of BHVs leaflets has been widely used for testing the efficacy of anti-calcification treatments, however, unlike the situation in humans, leaflets implanted into a murine model will not be able to elicit an αGal immune response because both donor and recipient species constitutively express the epitope. Objective This study evaluates the calcium deposition on commercial BHV using a new humanized murine αGal knockout (KO) animal model. Furtherly, the anti-calcification efficacy of a polyphenol-based treatment was deeply investigated. Methods and Results By using CRISPR/Cas9 approach an αGal KO mouse was created and used for the evaluation of the calcific propensity of original and polyphenols-treated BHV by subcutaneous implantation. The calcium quantification was carried out by plasma analysis; the immune response evaluation was performed by histology and immunological assays. Anti-αGal antibodies level in KO mice increases at least double after 2 months of implantation of original commercial BHV compared to WT mice, conversely, the polyphenols-based treatment seems to effectively mask the antigen to the KO mice’s immune system. Commercial leaflets explanted after 1 month from KO mice showed a four-time increased calcium deposition than what was observed on that explanted from WT. Polyphenol treatment prevents calcium deposition by over 99% in both KO and WT animals. Conclusions The implantation of commercial BHV leaflets significantly stimulates the KO mouse immune system resulting in massive production of anti-Gal antibodies and the exacerbation of the αGal-related calcific effect if compared with the WT mouse. The polyphenol-based treatment applied in this investigation showed an unexpected ability to inhibit the recognition of BHV xenoantigens by circulating antibodies completely preventing calcific depositions compared to the untreated counterpart.

19 October 2016 in European Journal of Histochemistry
Verified
Journal Article
Open access
PDF file
ARAntonio Rossi
Antonio Rossi
MOMaurizio Onisto
Maurizio Onisto
MSMichele Spina
Michele Spina
BZBarbara Zavan
Barbara Zavan
GBGloria Bellin
Gloria Bellin
MFMarco Franchi
Marco Franchi
Proceedings of the XXXVI National Meeting of the Italian Society for the Study of Connective Tissues (SISC)